Back to results
US 2025/0152686 A1Published application
Il-15-based fusions to il-12 and il-18
AssigneeAltor BioScience Corporation
InventorsWarren D. Marcus, Robert Newman, Bai Liu, Lijing You, Lin Kong, Peter Rhode, Hing C. Wong
Life of this patent
Estimating the term…
Abstract
The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-12 or IL-18.
Claims10
-40. (canceled)
A pharmaceutical composition comprising natural killer (NK) cells and an isolated soluble fusion protein complex comprising:
- a first soluble protein comprising an interleukin-15 (IL-15) polypeptide domain and an IL-12 polypeptide domain, and
- a second soluble protein comprising a soluble IL-15 receptor alpha sushi (IL-15RαSu) polypeptide domain and an IL-18 polypeptide domain,
- wherein the IL-15 polypeptide domain binds to the IL-15RαSu polypeptide domain to form the soluble fusion protein complex, wherein the pharmaceutical composition is formulated for administration.
Dependencies are inferred from the claim text.